Immune Thrombocytopenia: Difference between revisions
No edit summary |
|||
| Line 10: | Line 10: | ||
==[[Xyz historical perspective|Historical Perspective]]== | ==[[Xyz historical perspective|Historical Perspective]]== | ||
Immune Thrombocytopenia was described by Werlhof | |||
==[[Xyz classification|Classification]]== | ==[[Xyz classification|Classification]]== | ||
Revision as of 17:41, 4 December 2020
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Immune Thrombocytopenia On the Web |
|
American Roentgen Ray Society Images of Immune Thrombocytopenia |
|
Risk calculators and risk factors for Immune Thrombocytopenia |
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rahmah Al-Edresi, M.D.[2]
Synonyms and keywords:Idiopathic thrombocytopenic purpura, Immune thrombocytopenic purpura, Autoimmune thrombocytopenic purpura.
Overview
Historical Perspective
Immune Thrombocytopenia was described by Werlhof
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Interventions | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies